Literature DB >> 21196237

Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease.

Sunil Bhandari1.   

Abstract

Chronic kidney disease has been increasingly recognized as a risk factor for incident heart failure. Despite advances in chronic heart failure treatment, the prognosis remains poor. The annual mortality from all cardiovascular causes in the end stage renal disease population is significantly higher than the general population, accounting for more than half of all deaths in this group. The mechanisms underlying the enhanced susceptibility to myocardial ischemia in chronic kidney disease are not well defined. Traditional cardiovascular risk factors, although common in chronic kidney disease, do not exert the same impact as in the general population. The presence of "renal-specific" non-traditional risk factors including endothelial dysfunction, inflammation, oxidative stress, anaemia, proteinuria and changes in vitamin D metabolism (encompassing the complex interactions of calcium and phosphate metabolism, hyperparathyroidism and vascular calcification) play an important role in cardiovascular disease progression. An increased understanding of the array of metabolic changes/adaptations occurring in uraemic heart disease have allowed one to consider optimal management strategies and to develop new strategies for future management of uraemic heart disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21196237     DOI: 10.2741/3794

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  5 in total

1.  A renal transplant patient with abdominal discomfort, vomiting and diarrhoea for 1 week.

Authors:  Nancy Lutwak; Curt Dill
Journal:  BMJ Case Rep       Date:  2011-08-24

2.  Cardiac complications in end-stage renal disease: a shared care challenge.

Authors:  Xenophon Kassianides; Adil Hazara; Sunil Bhandari
Journal:  Br J Cardiol       Date:  2020-05-20

3.  Analysis of factors predicting mortality of new patients commencing renal replacement therapy 10 years of follow-up.

Authors:  Oliver T Browne; Victoria Allgar; Sunil Bhandari
Journal:  BMC Nephrol       Date:  2014-01-20       Impact factor: 2.388

4.  A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status.

Authors:  S Bhandari; V Allgar; A Lamplugh; I Macdougall; P A Kalra
Journal:  BMC Nephrol       Date:  2021-03-30       Impact factor: 2.388

5.  Arterio-Venous Fistula: Is it Critical for Prolonged Survival in the over 80's Starting Haemodialysis?

Authors:  Adam D Jakes; Poonam Jani; Victoria Allgar; Archie Lamplugh; Ahmed Zeidan; Sunil Bhandari
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.